Senseonics posts 91% jump in preliminary Q3 revenue

Senseonics Holdings, Inc. reported preliminary, unaudited revenue of approximately $8.1 million for the third quarter of 2025.

Rhea-AI Filing Summary

Senseonics Holdings, Inc. reported preliminary, unaudited revenue of approximately $8.1 million for the third quarter of 2025. This represents a 91% increase compared to the third quarter of 2024, primarily driven by approximately 160% growth in new U.S. patients over the prior year period.

The company emphasized that these figures are preliminary estimates based on information currently available, have not been reviewed or audited by its independent registered public accounting firm, and may change when full third quarter 2025 financial statements are finalized and reviewed.

Positive

• Preliminary Q3 2025 revenue growth: approximately $8.1 million, up 91% versus the third quarter of 2024, driven by about 160% growth in new U.S. patients.

Negative

• None.

Insights

Equity research analyst

Preliminary Q3 2025 revenue shows strong top-line acceleration but remains unaudited and subject to change.

The company reports preliminary, unaudited Q3 2025 revenue of $8.1 million, a 91% increase versus Q3 2024. Management attributes this to approximately 160% growth in new U.S. patients over the prior year, suggesting strong demand expansion for its offering during the quarter.

Because these figures are preliminary, they depend on the financial close process and review by the independent registered public accounting firm. The company highlights that actual reviewed results for the quarter ended September 30, 2025 could differ from these estimates and directs readers to previously disclosed risk factors for context.

Subsequent filings with full GAAP financial statements for the quarter ended September 30, 2025 will provide more detail on profitability, cash flow, and whether this pace of new patient growth translates into sustained revenue trends.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What preliminary Q3 2025 revenue did Senseonics (SENS) report?

Senseonics reported preliminary, unaudited revenue of approximately $8.1 million for the third quarter of 2025.

How did Senseonics' Q3 2025 revenue compare to Q3 2024?

The preliminary Q3 2025 revenue of about $8.1 million represents a 91% increase compared to the third quarter of 2024.

What drove Senseonics' revenue growth in Q3 2025?

The company states the revenue increase was driven by approximately 160% new patient growth in the U.S. over the prior year period.

Are Senseonics' Q3 2025 numbers final and audited?

No. The Q3 2025 figures are described as preliminary and unaudited, based on information available to management and subject to change after the financial close process and review by the independent registered public accounting firm.

What risks did Senseonics highlight regarding its preliminary Q3 2025 results?

Senseonics notes that actual results may differ materially from these forward-looking statements due to uncertainties in the financial close process and other factors described under "Risk Factors" in its prior Annual and Quarterly Reports.

Where can investors find the final Q3 2025 financial statements for Senseonics?

Final Q3 2025 financial statements, prepared in accordance with GAAP and reviewed by the independent registered public accounting firm, will be provided in the company’s subsequent SEC filings for the quarter ended September 30, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/07/2025 - 05:23 PM EDT Learn about SEC filing dates

false 0001616543 0001616543 2025-10-06 2025-10-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 6, 2025

SENSEONICS HOLDINGS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-37717		47-1210911
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

20451 Seneca Meadows Parkway
Germantown, MD 20876-7005

(Address of Principal Executive Office) (Zip Code)

Registrant's telephone number, including area code: (301) 515-7260

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	SENS	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

As previously reported, on October 6, 2025, Senseonics Holdings, Inc. (the “Company”) issued a press release announcing among other things, business updates, including certain preliminary, unaudited financial information for the quarter ended September 30, 2025, including reporting preliminary unaudited revenue of approximately $8.1 million in the third quarter of 2025, an increase of 91% versus the third quarter of 2024, driven by approximately 160% new patient growth in the U.S. over the prior year.

Forward Looking Statements

Any statements in this report about future expectations, plans and prospects for the Company, including the anticipated revenue results for the third quarter of 2025 constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the financial close process in connection with the finalization of the Company’s third quarter 2025 financial statements, as well as the review of such financial statements by the Company’s independent registered public accounting firm and such other factors as are set forth in the risk factors detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and subsequent reports filed with the Securities and Exchange Commission under the heading "Risk Factors." The forward-looking statements included in this report represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

Preliminary Unaudited Financial Information

The preliminary financial information presented in this report are estimates based on information available to management as of the date of this report, have not been reviewed or audited by the Company’s independent registered public accounting firm and are subject to change. There can be no assurance that the Company’s actual reviewed financial results as of and for the third quarter 2025 will not differ from the preliminary financial information presented in this report. The preliminary financial information presented in this report should not be viewed as a substitute for full financial statements prepared in accordance with GAAP and reviewed by the Company’s independent registered public accounting firm.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 7, 2025	SENSEONICS HOLDINGS, INC.
	By:	/s/ Rick Sullivan
	Name:	Rick Sullivan
	Title:	Chief Financial Officer